Amarin Corporation plc · Healthcare · Drug Manufacturers - General
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$13.82
−$0.30 (−2.10%) 4:00 PM ET
After hours$14.00
+$0.18 (+1.27%) 4:55 PM ET
Prev closePrevC$14.12
OpenOpen$14.02
Day highHigh$14.12
Day lowLow$13.76
VolumeVol50,808
Avg volAvgVol91,399
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$286.94M
P/E ratio
-3.45
FY Revenue
$226.73M
EPS
-4.01
Gross Margin
38.87%
Sector
Healthcare
AI report sections
BEARISH
AMRN
Amarin Corporation plc
Amarin Corp Plc combines moderately improving revenue and earnings trends with ongoing operating losses and negative operating cash flow. The share price sits in the upper half of its 52-week range with constructive short-term technical momentum, while valuation metrics such as P/B and EV/Sales appear undemanding relative to book value and sales. Short interest is modest, but the very high recent short volume ratio points to elevated positioning activity in the near term.
AI summarized at 6:19 PM ET, 2026-02-18
AI summary scores
INTRADAY:63SWING:57LONG:44
Volume vs average
Intraday (cumulative)
−45% (Below avg)
Vol/Avg: 0.55×
RSI
39.74(Weak)
Weak (30–40)
0255075100
MACD momentum
Intraday
-0.00 (Weak)
MACD: -0.01 Signal: -0.01
Short-Term
-0.10 (Weak)
MACD: -0.04 Signal: 0.06
Long-Term
-0.05 (Weak)
MACD: 0.01 Signal: 0.06
Intraday trend score
27.09
LOW18.09HIGH37.39
Latest news
AMRN•12 articles•Positive: 4Neutral: 1Negative: 0
NeutralGlobeNewswire Inc.• Recordati S.P.A.
RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION
Recordati reported strong financial performance in Q3 2025, with revenue up 12.2% to €1,956.2 million, driven by growth in Rare Diseases and Specialty & Primary Care segments. The company doubled its peak sales estimate for Isturisa to over €1.2 billion and expects Rare Diseases to approach 50% of total revenues in 2026.
Licensing agreement for Vazkepa with upfront payment of $25 million, expected modest revenues in 2025
PositiveGlobeNewswire Inc.• Amarin Corporation
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
Amarin presented a new post hoc analysis of the REDUCE-IT study demonstrating that icosapent ethyl (VASCEPA/VAZKEPA) significantly reduced cardiovascular events in high-risk patients, with consistent benefits observed in both aspirin users and non-users.
Company presented positive clinical research results reinforcing the cardiovascular benefits of their drug, highlighting potential expanded market opportunities and scientific validation
PositiveGlobeNewswire Inc.• Amarin Corporation
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
Amarin and HLS Therapeutics will present scientific data at the Canadian Cardiovascular Congress, highlighting the clinical value of Icosapent Ethyl (IPE) for cardiometabolic conditions and exploring EPA's mechanistic effects on cardiovascular health.
Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program
Amarin Corporation announced a 1-for-20 ratio change on its American Depositary Shares (ADSs) to increase the per-share market price and maintain its Nasdaq listing. The change is expected to take effect on April 11, 2025.
AMRNAmarin CorporationADSNasdaq listing
Sentiment note
The company is taking proactive measures to maintain its Nasdaq listing by increasing the per-share market price of its ADSs through a ratio change. This suggests the company is focused on addressing the issue and maintaining its public listing.
PositiveGlobeNewswire Inc.• N/A
Amarin Appoints Peter Fishman Chief Financial Officer
Amarin Corporation plc has appointed Peter Fishman as its new Chief Financial Officer, effective immediately. Fishman previously served as the company's Global Controller and principal financial and accounting officer.
The article announces the appointment of a new Chief Financial Officer, which suggests the company is making positive changes to its leadership and financial management.
UnknownGlobeNewswire Inc.• Amarin Corporation plc
Amarin Board of Directors Announces CEO Transition
-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities --
AMRNDirectors and Officers
UnknownGlobeNewswire Inc.• Amarin Corporation plc
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
-- Greek Ministry of Health approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in statin-treated adult patients with elevated triglycerides (≥ 150 mg/ml [≥ 1.7 mmol/l) and other high-risk characteristics as studied in REDUCE-IT1 -- -- Approval marks seventh national reimbursement of VAZKEPA® in Europe --
AMRNHealthProduct / Services Announcement
UnknownGlobeNewswire Inc.• Amarin Corporation plc
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin’s president and chief executive officer, is scheduled to participate in fireside chat at the 2024 H.C. Wainwright 2nd Annual BioConnect Investor Conference.
AMRNCalendar of Events
UnknownZacks Investment Research• Zacks Equity Research
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
Kymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the current cash balance to provide a runway into the first half of 2027.
SNYAMRNANIPKYMR
UnknownZacks Investment Research• Zacks Equity Research
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Here is how Amarin (AMRN) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
AMRNANIP
UnknownZacks Investment Research• Zacks Equity Research
Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall
Bausch's (BHC) first-quarter earnings and sales miss their respective estimates. Its shares fall in response to the results.
AMRNANIPBHCAMRX
UnknownZacks Investment Research• Zacks Equity Research
Amarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates
Amarin (AMRN) posts better-than-expected first-quarter 2024 results. Vascepa's sales in the United States continue to be hurt by generic competition.
LGNDAMRNANIPVYGR
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
